Noble Financial Predicts MariMed FY2026 Earnings

MariMed Inc. (OTCMKTS:MRMD) – Investment analysts at Noble Financial issued their FY2026 earnings per share estimates for shares of MariMed in a research note issued on Monday, March 16th. Noble Financial analyst J. Gomes expects that the company will earn ($0.05) per share for the year.

Separately, Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One investment analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

MariMed Stock Performance

MRMD opened at $0.08 on Wednesday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 0.38 and a current ratio of 1.00. MariMed has a 52-week low of $0.07 and a 52-week high of $0.23. The firm has a market cap of $30.66 million, a P/E ratio of -2.58 and a beta of 1.11. The business’s fifty day moving average is $0.09 and its 200-day moving average is $0.11.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.